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Title Page
Study Design:  Retrospective Case Series 
Objective :  To demonstrate the microbial trends of spinal surgical site infections(SSI) in patients who had 
previously received crystallized vancomycin in the operative bed.  
Summary of Background Data: Prior large, case control series demonstrate the significant decrease in SSI with the 
administration of vancomycin in the wound bed. 
Methods:   A single institution, electronic database search was conducted for all spinal surgery patients who had 
received prophylactic crystalline vancomycin powder in the wound bed.  Patient’s with a prior history of wound 
infection, intrathecal pumps, or spinal stimulators were excluded  
Results:  981 consecutive patients (494 male, 487 female, mean age 59.4 years, range 16-95 years) were identified 
from January 2011 to June 2013.  The average dose of vancomycin powder was 1.13 grams(range: 1-6 grams). 66 
patients (6.71%) were diagnosed with a SSI of which 51 patients had positive wound cultures (5.2%).    Of the 51 
positive cultures the most common organism  was Staphylococcus aureus.  The average dose of vancomycin was 
1.3 grams in the 38 cases where a gram-positive organism was cultured.  A number of gram-negative infections 
were encountered such as Serratia marcescens, Enterobacter aerogenes, Bacteroides fragilis, Enterobacter cloacae, 
Citrobacter koseri and Pseudomonas aeruginosa.  The average dose of vancomycin was 1.2 grams in 23 cases 
where a gram negative infection was cultured.  15 of the 51 (29.4%) positive-cultures were polymicrobial.  8 (53%) 
of these 15 polymicrobial cultures contained three or more distinct organisms.   
Conclusions 
Prophylactic intraoperative vancomycin use in the wound bed in spinal surgery may increase the 
incidence of gram-negative or polymicrobial spinal infections.  The use of intraoperative vancomycin may correlate 
with postoperative seromas, due to the high incidence of non-positive cultures.  Large, randomized, prospective 
trials are needed to demonstrate causation and dose-response relationship. 
 
*Structured Abstract (300 words)
Key Points:   
1.  Prophylactic intraoperative vancomycin powder may correlate with an increased incidence of gram-negative or 
polymicrobial spine infections, as well as postoperative seromas.   
2.  This report is the first, large series study of spinal surgery patients that gives credence to a potential concern 
that intraoperative vancomycin powder could select for gram-negative organisms.   
3.  Large, randomized, prospective trials are needed to elucidate causation, dose-response relationship and cost 
implications. 
 
*Key Points (3-5 main points of the article)
Mini Abstract 
981 patients receiving intraoperative vancomycin were retrospectively reviewed, with 51 patients being culture-
positive (5.2%).    Many of these were infections were gram-negative and polymicrobial infections, giving credence 
to the concern that intraoperative vancomycin powder has a significant impact on microbial trends.   
 
*Mini Abstract (50 words)
1 
 
 1 
Introduction 2 
 Interest in quality improvement and cost-containment measures in spinal surgery is an ongoing driving 3 
force in evidence-based medicine.  One obstacle to lowering healthcare cost in spine surgery is the not infrequent 4 
incidence of surgical site infection (SSI), with reports ranging from 0.7 to 11.9%.
1
  This poses a significant challenge 5 
for cost reduction in spinal surgery, as it is estimated that the escalated cost of care for an infected patient is up to 6 
four-times.
2
  This is especially significant since reimbursements are being phased out for postoperative SSI.  7 
Retrospective evidence has demonstrated the decrease in incidence of SSI with the use of vancomycin in the 8 
wound bed.
3-8
  Because prior estimates place the additional costs of a SSI at 33,705 USD per infection,
4
  the use of 9 
vancomycin prophylaxis in the wound may save up to 438,165 US Dollars per 100 patients.
4
 10 
 The present retrospective case series serves to highlight the characteristics of vancomycin powder use 11 
intraoperatively in a large series, with a comprehensive characterization of postoperative infections in patients 12 
who have been treated with vancomycin to their spinal wound.  Because of a theoretical concern for growing 13 
organism resistance with the aggressive use of broad-spectrum antibiotics, the authors hypothesize that a similar 14 
phenomenon could occur with the use of wound vancomycin. With the widespread use of vancomycin 15 
intraoperatively, a survey of the postoperative infections in patients treated with vancomycin may reveal 16 
superinfections with uncommon organisms, a result of selective pressures exerted by vancomycin on ambient 17 
flora.    18 
Methods 19 
Electronic Search  20 
Institutional review board approval was obtained for this study.  A retrospective electronic chart review 21 
was conducted from January 2011 to June 2013 for all spinal surgery patients receiving intraoperative vancomycin 22 
at a single institution.  Patients who underwent spinal procedures for degenerative disease, trauma, pain, and 23 
scoliosis were included.  Mean age, gender, BMI, and surgical procedure were recorded.   24 
*Manuscript Text (must include page numbers)
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A query was performed for all patients who underwent spinal surgery and had also received dry, 25 
crystallized vancomycin in the wound bed.  Per attending preference, either 1 or 2 grams of crystallized 26 
vancomycin was evenly distributed through the subfascial and epifascial layers; this was often a determination 27 
based on the size of the wound bed.  In rare cases, up to 6 grams were reportedly used.  Preoperative antibiotics 28 
were administered one hour prior to skin incision with 1000 mg of intravenous cefazolin.  Patients who had a 29 
cephalosporin allergy underwent intravenous infusion with 1000 mg vancomycin (2000 if over 70kg).  30 
Postoperative subfascial and epifascial drainage catheters were removed at the discretion of the spinal surgeon 31 
which varied typically from 3-5 days postoperatively or when drainage output decreased below 30cc in an 8 hour 32 
period.  Postoperative antibiotics are standardized for all surgical patients with cephalosporin given two more 33 
doses every 8 hours and in the case of vancomycin, one more dose was given twelve hours after the first dose. 34 
The incidence and characteristics of patients with surgical site infections were evaluated.  In all cases, 35 
surgical site infections underwent antibiotic irrigation and debridement of devitalized tissue.  Risk factors in those 36 
treated with vancomycin who developed a postoperative surgical site infection (SSI) were evaluated.  For patients 37 
who had a postoperative infection, organisms cultured and their frequency were characterized.  All patients who 38 
went to the operating room and had a surgical debridement were considered a SSI.  Postoperative cultures that 39 
were negative were still considered as a wound infection, despite the results, given the possibility that 40 
postoperative vancomycin could contaminate the culture. 41 
Exclusion criteria included any patient with a history of a prior spinal infection as well as those whose 42 
primary indication was chronic pain management, including intrathecal pumps and spinal cord stimulators.  43 
Comparison  was made to recent historical data on overall spine infections from previously published literature 44 
about overall spine infections.
9
 45 
 46 
SSI Criteria and Decision-making Algorithm 47 
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The decision to undergo a wound washout, and thus the criteria for diagnosis of a SSI was ultimately at 48 
the discretion of the attending surgeon.  For all patients with wound drainage or minimal breakdown with 49 
drainage, irrigation with debridement and definitive closure in the operating room was performed.  In the absence 50 
of wound drainage, the clinical decision to proceed with a washout was performed on a case-by-case basis from a 51 
combination of the following signs, symptoms, and objective evidence:  fevers, persistent pain, erythema, MRI 52 
evidence of infection, or elevated laboratory markers such as erythrocyte sedimentation rate, c-reactive protein, 53 
and white cell count.   54 
Statistical Analysis 55 
 Organism distribution was evaluated from both vancomycin cohort and historic control data with 56 
a two-tailed t-test.  P-values of ≤ 0.05 were considered statistically significant. Statistical analysis was carried out 57 
with a statistical software package (JMP v 8.0.1, SAS institute 2012). 58 
 59 
  60 
 61 
Results 62 
 In an electronic search of the hospital medical record system, 981 consecutive patients from Jan 2011 63 
until June 2013 underwent spinal surgery and had received intraoperative vancomycin in the skin edges, muscle, 64 
fascia, and wound bed, without intentional mixing into the bone graft (494 male, 487 female, mean age 59.4 years, 65 
range 16-95 years).  The average dose of vancomycin powder was 1.13 grams (Range: 0.5-6 gm). The most 66 
common doses for the patients was 1 gram (849 patients) and 2 grams (123 patients).  The mean BMI of the 67 
patient population was 30.27.  Table 1 lists the indications for the surgical procedures, although there was an 68 
overlap of degenerative diseases as well as other indications.  Overall in this series, 66 patients (6.71%) were 69 
diagnosed with a surgical site infection (SSI). All of these 66 patients received a wound irrigation, debridement, and 70 
drain placement per the aforementioned protocol.   71 
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All patients who returned to the operating room for postoperative infection were cultured 72 
intraoperatively.  Fifty-one patients had positive wound cultures (5.2%).  In 15 patients, no organism growth was 73 
noted over 72 hours of culturing.  The most common organism cultured intraoperatively was Staphylococcus 74 
aureus (table 2).  A number of gram-negative infections were encountered such as Serratia marcescens, 75 
Enterobacter aerogenes, Bacteroides fragilis, Enterobacter cloacae, Citrobacter koseri, Pseudomonas aeruginosa.  76 
15 of the 51 (29.4%) positive-cultures were polymicrobial.  8 (53%) of these 15 polymicrobial cultures contained 77 
three or more distinct organisms.  Of the positive wound cultures, the majority were cultured from the lumbar 78 
spine (n=35, 67%), followed by the thoracic (10, 20%) and cervical spine (6, 13%) (table 3). 79 
In the patients who were cultured for wound infection, the most common preoperative indication for the 80 
index surgery was degenerative disease: spinal stenosis, degenerative disk disease, spondylolisthesis, and cervical 81 
spondylotic myelopathy.  Trauma was an indication in nine of the positively cultured patients. 82 
Arthrodesis 83 
Out of 981 total patients, 865 patients had an instrumented fusion, and 187 underwent only a 84 
decompression most often for a lumbar disc herniation. The mean number of levels fused was 2.4 (Range: 1-16).  85 
All 981 patients underwent a decompressive surgery.  There was no significant association between the number of 86 
fusion levels and incidence of SSI (table 5). 87 
Discussion  88 
 Evidence from previously reported case series clearly demonstrates the utility of surgical site vancomycin 89 
for lowering spinal wound infection rates (table 5).  Vancomycin powder appears to be effective for instrumented 90 
and non-instrumented fusions equally, as well as for decompressions.
6, 8, 10
  Prior case series demonstrated efficacy 91 
regardless of the mixture of vancomycin in the bone graft or not.
8
   92 
Prior Studies on Intraoperative Vancomycin Use  93 
Strom et al.
8
 evaluated 253 patients who underwent a lumbar decompression and fusion and had 94 
received 1 gram of intraoperative vancomycin.  Compared to well-matched controls at the same institution, a 95 
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dramatic reduction in the infection rate was noted (11% to 0%, P<0.0001).  This study excluded superficial wound 96 
infections due to the variability in the presentation.  Vancomycin powder was applied to the muscle, fascia, and 97 
deep tissue, but not intermingled with the bone graft.  This study had a well-matched control group.  The authors 98 
also examined the vancomycin levels in blood, finding a low level, suggestive of minimal systemic absorption, and a 99 
high-level in the postoperative drains to day 3, evidence of a lasting antimicrobial effect. There were no adverse 100 
effects related to vancomycin use.  101 
Sweet et al.
3
 evaluated the use of intraoperative vancomycin in the thoracolumbar patient population, 102 
expanding the cohort size to 911, with a significantly larger 2 gram vancomycin dose.  One gram of vancomycin 103 
was mixed with the bone graft at least 15 minutes prior to placement, with the remaining vancomycin spread 104 
evenly in the wound.  Similar results were obtained, with dramatic reduction in deep wound infection (2.6 to 105 
0.2%).  Like previous studies, the superficial wound infections were excluded.  106 
O’Neill and colleagues
5
 reported their experience in a retrospective review of 216 patients who 107 
underwent posterior instrumented fusion for traumatic spine fractures, finding a decrease in infection from 13% in 108 
controls to 0% in the treatment group which had received 1 gram of intraoperative vancomycin to the wound bed, 109 
without mixing the vancomycin in the bone graft.  In this study, superficial infections were not excluded, where in 110 
the control group, there were 2 superficial, and 5 deep wound infections that required operative irrigation and 111 
debridement.  112 
 Molinari and colleagues
6
 evaluated their experience with 1512 patients who underwent prophylactic 113 
vancomycin application to spinal wounds, resulting in only 15 infections (0.99%).  This number is influenced by the 114 
fact that only deep infections were reported, as they report that 1 gram of vancomycin was only placed beneath 115 
the fascia, and like most other studies was not mixed in with the bone graft.  There was no control group for 116 
comparison.    117 
 118 
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Our reported infection rate of 6.4% was of those patients who went to the operating room with an 119 
infection.  Those patients who were cultured and had an identified organism totaled 5.2% (where seronegative 120 
collections were excluded).   With comparison to one historic control cohort study from 2005 to 2009, a mean 121 
incidence of spine infection of 3.4% was reported, with a range as high as 4%.
9
   The lower rate of spine infection 122 
mentioned in the previously reported series as well as from other previous series (table 4) was most likely 123 
accounted for by the less stringent selection criteria in this present study.  Additionally, in our present study, the 124 
administration of vancomycin was at the discretion of the surgery which undoubtedly was biased towards higher 125 
risk patients.  The purpose of this manuscript was to capture potential infections after use of intraoperative 126 
vancomycin with a hypothesis that the selective pressures of vancomycin could lead to the emergence of gram-127 
negative and atypical gram-positive organisms (table 2).   128 
Comparison to a previous report by Rao et al in 2008, evaluated the outcomes of 1587 patients who 129 
underwent spinal surgery that year, finding 57 deep SSI (3.7%, P=0.049).
11
  Interestingly, in this series of patients 130 
who did not have vancomycin powder, 67% of the infections contained Staphylococcus aureus, while in our 131 
present series, S. Aureus was cultured 57% of the time.  Gram-negative organisms occurred with a greater 132 
frequency in the vancomycin treatment group (60% vs. 21%, P =0.0001).  Polymicrobial infections were 133 
encountered 15% of the time in prior historical controls and 19% in our present series (P=0.9638) (table 2).   Prior 134 
publications exclude superficial infections for the reason of clinical ambiguity and the difficulty in culturing the 135 
wound without contamination with the skin flora.  Since cultures were taken in the intraoperative setting, where 136 
the skin has been sterilized and the culture taken from the fascia directly, as well as subfascial soft tissues, it is 137 
unlikely that normal skin flora contaminated our cultures.  In all, as concluded in systematic reviews of SSI in spinal 138 
surgery, lack of standardized definitions of SSI and inconsistencies with methodology and error reporting introduce 139 
significant bias and may serve as the source of variation in these SSI rates.
12
 140 
 In our series, we find an overabundance of gram-negative organisms (Table 2), lending support to our 141 
hypothesis that intraoperative vancomycin provides a selective pressure resulting in increased prevalence of gram-142 
negative and polymicrobial wound infections.  In our two cases of fungal infection, the patients were not diabetic, 143 
nor did they have prior radiation, or an immunocompromised status.   One future consideration would be to 144 
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broaden the antibiotic coverage, adding another antibiotic to vancomycin in the wound to cover these gram 145 
negative organisms.  This is likely a safe measure as prior studies have shown the minimal systemic absorption and 146 
high concentration locally by measurement in the drain output.
8
  147 
Study Limitations 148 
 Our study is limited by the lack of a control cohort.  However, the purpose was not to repeat a prior 149 
vancomcycin control cohort study as was previously performed.
3-7
  Given that a recently published series  on the 150 
rate of spine infection existed, this was felt adequate for a historical figure of comparison.
9, 11
  The present study, 151 
however, differs from this  previously published data  in our selection criteria. This study includes different spinal 152 
surgeons as well as a more diverse sample of patients who underwent intraoperative administration of 153 
vancomycin.   Also, selection bias from the annual fluctuations in infection rates that occur
5
 is relevant in this 154 
comparison.  Here, we compare a prior 12 month historic control cohort to an 18 month, nonconsecutive cohort.
9
  155 
In addition to the significant increase in gram-negative organism on historic controls, a preponderance of the 156 
literature reports little if any gram-negative or polymicrobial infections once vancomycin powder is introduced.  157 
This discordance is important since it could also demonstrate the emergence of drug-resistant organisms.  More 158 
prospective studies need to be done to demonstrate this cause-effect releationship.   159 
Conclusion 160 
Prophylactic Intraoperative vancomycin use in the wound bed in spinal surgery may increase the 161 
incidence of gram-negative or polymicrobial spinal infections.  The use of intraoperative vancomycin may correlate 162 
with postoperative seromas.  Large, randomized, prospective trials are needed to elucidate causation, dose-163 
response relationship and cost implications. 164 
 165 
 166 
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Tables 
Table 1.  Surgical Indications by Diagnosis 
Indication N, uninfected % N, Diagnosis of 
SSI  
% 
Degenerative disk disease 143 10.27 2 1.82 
Stenosis 478 34.34 51 46.36 
Spondylolisthesis 322 23.13 28 25.45 
Deformity Correction 209 15.01 14 12.73 
Neoplasm 36 2.59 2 1.82 
Trauma 90 6.47 9 8.18 
Adjacent level 
disease/pseudoarthrosis 
62 4.45 0 0.00 
Others* 52 3.74 4 3.64 
*- Other secondary or multifactorial pathologies include: spondylosis (34), myelopathy (31), arachnoid 
cyst/pseudomeningocoele (9), OPLL (3), ankylosing spondylitis (5), central cord syndrome (6), cauda equina 
syndrome (9), spondyloptosis (1), charcot spine (1). 
 
Table 2. Cultured Organisms from Culture positive Surgical Site Infections* 
Organism N, Cultured  (n=51) Historic Control(n=57)8 P= 0.0490 
Gram Positive 44(86.3) 46(80.1%) 0.4460 
Staphylococcus aureus(MSSA) 15 25 0.1199 
Streptococcus mutans 1 n/a n/a 
Coagulase negative 
staphylococcus  
17 16 0.5516 
Enterococcus faecalis (Group D 
streptococci) (VRE) 
1 5 0.1206 
MRSA 11 11 1.0 
Gram Negative 31(60.7%) 12(21%) 0.0001 
Corynebacteria sp. 1 n/a n/a 
E. coli 9 n/a n/a 
Klebsiella pneumoniae 7 n/a n/a 
Proteus mirabilis/other proteus 
species 
7 n/a n/a 
Pseudomonas aeruginosa 2 n/a n/a 
Enterobacter aerogenes 1 n/a n/a 
Serratia marcescens 1 n/a n/a 
Bacteroides fragilis 1 n/a n/a 
Enterobacter cloacae 1 n/a n/a 
Citrobacter koseri 1 n/a n/a 
Culture negative 15   
Fungal 2   
Polymicrobial 15 17 0.9638 
 
Table 3: Positive Wound Culture by Region 
Tables
 Incidence 
Cervical 35 (67%) 
Thoracic 10 (20%) 
Lumbar/ Lumbosacral 6  (13%) 
 
Table 4: SSI and Arthrodesis 
Surgical Treatment N Incidence of SSI 
Arthrodesis 865 45 (88%) 
Decompression 925 6 (12%) 
 
Table 5: Prior Studies of Intraoperative Vancomycin in Spinal Surgery 
Manuscript Autho
r 
Journa
l 
Year N Design Spin
e 
Method
s 
Infectio
n Rate 
control 
Infectio
n Rate 
SSV 
P Value Addt’l 
Outcome
s 
Comparative 
effectivenes
s of vanco in 
spinal 
wounds 
Godil 
et al 
JNS 
Spine  
201
3 
110 Retrosp
ective 
C SSV vs. 
control 
13% 
control  
O% 0.02 33,705 
USD per 
infection, 
438,165 
USD 
saved per 
100 
patients 
with SSV 
Intrawound 
Vanco for TL 
Fusion 
prophylaxis 
Sweet Spine 201
1 
173
2 
Retrosp
ective 
TL SSV vs. 
control  
2.6 0.2 <0.0001 Control 
group 
org- s. 
aureus/ 
SSV 
infections
- no 
organism 
Lumbar 
laminectom
y and fusion 
with routine 
application 
of 
vancomycin 
Strom 
et al 
Clin 
Neurol 
and 
Neuros
urg 
201
3 
253 Retrosp
ective 
Lum
bar 
SSV vs. 
control 
11 0 0.0008 Significan
t 
reduction 
in 
infection 
with 
routine 
vancomyc
in use 
Reduced SSI 
in instr. 
Fusions for 
trauma in 
posterior 
O’Neill 
et al 
Spine J 201
1 
110 Retrosp
ective 
CTL 
sp 
SSV vs. 
control 
13 0 0.02 Significan
t 
reduction 
in 
infection 
  
 
 
spinal 
surgery 
control 
Prophylactic
SSV 
Molina
ri 
Eur Sp 
J 
201
2 
151
2 
Retrosp
ective 
A or 
P, 
CTL 
sp 
All w/ 
SSV 
N/A 0.99% N/A Infection 
rate for 
instrumen
ted vs. 
uninstru
mented 
1.20 vs. 
0.82%, 
respectiv
ely. S. 
aureus 
was most 
isolated 
6/15 
infections 
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